JP2022547061A5 - - Google Patents
Info
- Publication number
- JP2022547061A5 JP2022547061A5 JP2022514608A JP2022514608A JP2022547061A5 JP 2022547061 A5 JP2022547061 A5 JP 2022547061A5 JP 2022514608 A JP2022514608 A JP 2022514608A JP 2022514608 A JP2022514608 A JP 2022514608A JP 2022547061 A5 JP2022547061 A5 JP 2022547061A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical product
- human anti
- product according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025097923A JP2025148350A (ja) | 2019-09-05 | 2025-06-11 | 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962896224P | 2019-09-05 | 2019-09-05 | |
| US62/896,224 | 2019-09-05 | ||
| PCT/EP2020/074714 WO2021043955A1 (en) | 2019-09-05 | 2020-09-04 | Compositions and methods for treating extensive stage small cell lung cancer (es-sclc) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025097923A Division JP2025148350A (ja) | 2019-09-05 | 2025-06-11 | 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547061A JP2022547061A (ja) | 2022-11-10 |
| JP2022547061A5 true JP2022547061A5 (enExample) | 2023-09-11 |
Family
ID=72521575
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514608A Pending JP2022547061A (ja) | 2019-09-05 | 2020-09-04 | 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法 |
| JP2025097923A Pending JP2025148350A (ja) | 2019-09-05 | 2025-06-11 | 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025097923A Pending JP2025148350A (ja) | 2019-09-05 | 2025-06-11 | 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12012453B2 (enExample) |
| EP (1) | EP4025249A1 (enExample) |
| JP (2) | JP2022547061A (enExample) |
| KR (1) | KR20220058601A (enExample) |
| CN (1) | CN114340673A (enExample) |
| AU (2) | AU2020342713A1 (enExample) |
| CA (1) | CA3151838A1 (enExample) |
| IL (1) | IL290834A (enExample) |
| TW (1) | TWI907357B (enExample) |
| WO (1) | WO2021043955A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023185720A1 (zh) * | 2022-03-28 | 2023-10-05 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| TW202602492A (zh) * | 2024-04-05 | 2026-01-16 | 瑞典商阿斯特捷利康公司 | 局限期小細胞肺癌之治療 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| US20180079814A1 (en) * | 2015-04-01 | 2018-03-22 | Medimmune Limited | Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| EP3747472B1 (en) * | 2015-09-15 | 2024-04-03 | Acerta Pharma B.V. | Therapeutic combinations of a cd19 inhibitor and a btk inhibitor |
| TW201741337A (zh) * | 2016-05-13 | 2017-12-01 | 麥迪紐有限責任公司 | ＣＤ４０Ｌ-Ｆｃ融合多肽及其使用方法 |
| RU2765997C2 (ru) * | 2017-03-30 | 2022-02-07 | Мерк Патент Гмбх | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования |
| MY205645A (en) * | 2018-06-23 | 2024-11-02 | Genentech Inc | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
-
2020
- 2020-09-04 US US17/012,643 patent/US12012453B2/en active Active
- 2020-09-04 TW TW109130442A patent/TWI907357B/zh active
- 2020-09-04 EP EP20772218.2A patent/EP4025249A1/en active Pending
- 2020-09-04 CN CN202080062489.9A patent/CN114340673A/zh active Pending
- 2020-09-04 CA CA3151838A patent/CA3151838A1/en active Pending
- 2020-09-04 AU AU2020342713A patent/AU2020342713A1/en not_active Abandoned
- 2020-09-04 WO PCT/EP2020/074714 patent/WO2021043955A1/en not_active Ceased
- 2020-09-04 KR KR1020227011152A patent/KR20220058601A/ko active Pending
- 2020-09-04 JP JP2022514608A patent/JP2022547061A/ja active Pending
-
2022
- 2022-02-23 IL IL290834A patent/IL290834A/en unknown
-
2024
- 2024-05-07 US US18/657,210 patent/US20240376206A1/en active Pending
-
2025
- 2025-04-17 AU AU2025202735A patent/AU2025202735A1/en active Pending
- 2025-06-11 JP JP2025097923A patent/JP2025148350A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3458053B1 (en) | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| US12295962B2 (en) | Polymorphic compounds and uses thereof | |
| JP2022543062A5 (enExample) | ||
| EP3939610A1 (en) | Combined pharmaceutical composition for treating small cell lung cancer | |
| JP2023551559A5 (enExample) | ||
| EP4512421A1 (en) | Drug combination of anti-tim-3 antibody and anti-pd-1 antibody | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| JP2019516767A (ja) | 癌の治療のためのペンブロリズマブとアベマシクリブとの組合せ | |
| CN113811298B (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| US20210353648A1 (en) | Grapiprant unit dosage forms | |
| JP2022547061A5 (enExample) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2021530502A5 (enExample) | ||
| JP2024521105A5 (enExample) | ||
| CN115052628A (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| JP2011506607A5 (enExample) | ||
| JP2022514561A5 (enExample) | ||
| JP2024539476A5 (enExample) | ||
| JP2023500480A5 (enExample) | ||
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| JP7824627B2 (ja) | 癌療法のためのイアダデムスタット（ｉａｄａｄｅｍｓｔａｔ）の組み合わせ物 | |
| JP2025526402A5 (enExample) | ||
| TWI671072B (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 | |
| JP2024503379A5 (enExample) |